Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
Ferreri
Andrés J M
AJ
Dognini
Giuseppina P
GP
Govi
Silvia
S
Crocchiolo
Roberto
R
Bouzani
Maria
M
Bollinger
Claudia R
CR
D'Incan
Michel
M
Delaporte
Emmanuel
E
Hamadani
Mehdi
M
Jardin
Fabrice
F
Martusewicz-Boros
Magdalena
M
Montanari
Mauro
M
Szomor
Arpad
A
Zucca
Emanuele
E
Cavalli
Franco
F
Ponzoni
Maurilio
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab